论文部分内容阅读
本文通过1997年对36例上呼吸道感染应用病毒唑(0.5%～1%)滴鼻与23例病毒唑(10～15mg/kg/天)静脉用药进行对比分析,结果表明治疗组与对照组的临床疗效无显著差异(P>0.05),提示婴幼儿早期使用病毒唑滴鼻治疗上呼吸道感染,安全可靠,显效迅速。一、一般资料:上呼吸道感染患儿多起病较急,伴有发热、流涕、鼻塞、喷嚏等症状,抽取1997年病程小于3天的病例,随
In this paper, 36 cases of upper respiratory tract infection in 1997 with ribavirin (0.5% ~ 1%) intranasal and 23 cases of ribavirin (10 ~ 15mg / kg / day) intravenous drug comparison analysis showed that the treatment group and the control group Clinical efficacy was no significant difference (P> 0.05), suggesting that infants and young children early use of viral azole nasal drops treatment of upper respiratory tract infection, safe and reliable, effective rapidly. First, the general information: More children with upper respiratory tract infection more acute onset, accompanied by fever, runny nose, stuffy nose, sneezing and other symptoms, the duration of less than 3 days in 1997 to extract cases, with